PhD, Pharmaceutical Chemistry, The Ohio State University, 2000
BS, Molecular and Physical Chemistry, Moscow Institute of Science and Technology, 1994
Director, Pharmaceutical Sciences, Esperion Therapeutics (2000-2005)
Sr.Director,Pharmaceutical Sciences, Cerenis Therapeutics (2006-2011)
Dr. Schwendeman’s long-term research goal is to design highly potent synthetic high-density lipoprotein (HDL) nanoparticles for treatment of atherosclerosis. These ~8-10 nm size particles mimic the natural HDL function of cholesterol removal from arterial plaques, and subsequent cholesterol transport to the liver for elimination. For the past 12 years, Dr. Schwendeman has been involved in discovery and clinical development of this class of nanomedicines up to phase 2 clinical trials in patients with Acute Coronary Syndrome at local biotech companies (CER-001 at Cerenis Therapeutics and ETC-216 at Esperion Therapeutics). Her principal current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency and designing short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main protein component of HDL. Her laboratory is also interested in using synthetic HDL nanoparticles for drug delivery purposes as well as studying HDL for treatment of sepsis and Alzheimer's disease, and designing artificial HDL-based on gold nanoparticles.
Dasseux, J.-L., Schwendeman, A. S., and Zhu, L. Apolipoprotein A-I Mimics. US Patent Application 2010/0267631, 2010.
Oniciu, D. C., Dasseux, J.-L., Schwendeman, A. S., Sy, G. A. and Ackermann, R. M. Lipoprotein complexes manufacturing and uses thereof. US Provisional Patent Application Serial no. 61/487263, 2011.
Lalwani, N., Drake, S., Watson, C., Shenderova, A., Rodrigueza, W, Bisgaier, C., and Dasseux, J.-L. ETC-642, a Novel HDL Mimetic, Rapidly Elevates HDL-Associated Cholesterol Following Intravenous Administration in Rats, Rabbits, and Nonhuman Primates. Artherosclerosis, Thrombosis and Vascular Biology, 24 (5) 2004.
Keyserling, C. H., Hunt, T. L., Klepp, H. M., Barbaras, R., Schwendeman, A., Lalwani, N., and Dasseux, J.- L. A First-In-Human, Randomized, Double-Blind, Ascending Single-Dose, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CER-001 in Healthy Dyslipidemic Volunteers. Proceedings of American Heart Association Conference, 2011.